Improvement after a supplement is not the same as a comparative result
Start with the comparison. A before-and-after change alone cannot isolate the contribution of an ingredient.
Ginkgo
Selected research topic
Immune and respiratory health
Some publications still need interpretation checks and are kept separate from the findings below.
- Publications for this topic
- 2
- Human comparison publications
- 0
- Publications needing review
- 2
This result is held for interpretation. That does not mean research found no effect.
Outcome groups needing additional review (1)
- infection rate · Distinct papers needing additional review: 1Evidence criteria check: 1
One paper can appear under multiple measured outcomes or review reasons, so these counts should not be added together.
Representative outcome and study details
Some findings are held for review
Some papers have not cleared source or result review, so their findings are not summarized yet.
No confirmed result is available to summarize with study conditions.
1 publications linked to this result (1 awaiting review included)
- Those papers are not summarized until review is complete.
Data coverage and detailed study classifications
Paper counts are separated by research topic below. One paper may contribute to multiple findings.
Analysis status: Public-ready
Ingredient analysis date:
How the grade was determined: C
The 8.4 evidence score includes 1 independent human studies and 1 clinical studies in the representative benefit area. The C tier remains conservative because of limited repetition across independent human clinical studies, too few clinical findings with an explicit effect direction.
The grade is based mainly on the research area with the most evidence. It does not mean the same result was found in other areas.
Papers linked to this ingredient overall: 115
Papers linked to this topic 2 · distinct papers 2 · comparison findings need further review · papers needing additional review 2
A publication may appear in more than one count. These numbers should not be added. Ingredient-wide papers, topic-linked papers, and sources in outcome groups use different scopes. Adding source counts may count the same paper more than once.
- infection rate: Sources represented in this measurement group: 1 · Distinct papers with human comparisons for this outcome: 0
What the research found
infection rate
The study needs further checking before its result can be interpreted.
Animal study · indirect · Ingredient combination · Patient group
This finding comes from animal or cell research. It does not establish the same effect in people.
Several ingredients were used together. This does not establish the effect of this ingredient alone or synergy.
The comparison could not be confirmed.
Analysis coverage and paper counts
1 paper · 1 measured outcome
1 papers held from direction counts
Direction counts are distinct papers within each row. Outcome contributions count endpoint results, so one paper may contribute more than once.
Unspecified measured outcome
The study needs further checking before its result can be interpreted.
Review · Ingredient combination · Patient group
Several ingredients were used together. This does not establish the effect of this ingredient alone or synergy.
The comparison could not be confirmed.
Analysis coverage and paper counts
1 paper · 1 measured outcome
1 papers held from direction counts
Review overlap with primary papers is unknown; counts stay separate.
Direction counts are distinct papers within each row. Outcome contributions count endpoint results, so one paper may contribute more than once.
How to read research findings
How should I read research findings?
Research guidesNo clear difference and an uninterpretable result are different
A reported null comparison contains a result. An abstract without an interpretable comparison leaves a question unresolved.
Paper counts and study counts are different
Count original research separately from research that reanalyzes it. Publication volume is neither replication nor a quality rating.
Side effects and combination findings
Findings from this ingredient alone are shown separately from those involving another supplement or medication.
No reviewed caution rules are available yet. Reported caution findings are shown below.
Findings to review with care
Side effects reported for the ingredient alone are separated from findings involving another supplement or medication.
Side effects reported with this ingredient alone
Symptoms or adverse events reported in studies without another active ingredient.
liver injury1 papers
Hepatotoxicity observed in rodent studies of a commercially available unfinished GbE product.Animal studies · Animal studyembryotoxicity1 papers
Ginkgo biloba leaf extract contains ginkgolic acids that cause embryotoxicity, cytotoxicity, neurotoxicity, and enzyme inhibition.Cell studies · Systematic reviewneurotoxicity1 papers
A limited number of studies indicate that ginkgolic acids may have adverse effects on the nervous system.Human studies · Systematic reviewnephrotoxicity1 papers
A limited number of studies indicate that ginkgolic acids may exhibit nephrotoxicity.Human studies · Systematic reviewhepatotoxicity1 papers
Ginkgolic acids can induce significant hepatic damage by promoting cellular apoptosis, oxidative stress, and disruption of metabolic processes.Human studies · Systematic reviewendotoxins and ginkgolic acids toxicity1 papers
The review reports that endotoxins and ginkgolic acids present in Ginkgo biloba are identified as dominant toxic components.Human studies · Systematic reviewDropout due to adverse events1 papers
Meta-analysis showed dropout rates due to side effects were significantly lower with Ginkgo biloba than placebo (OR = 1.72, 95% CI [1.06, 2.80]), indicating a favorable safety profile.Human studies · Meta-analysisdermatotoxicity1 papers
A limited number of studies indicate that ginkgolic acids may have adverse effects on the skin.Human studies · Systematic reviewCautions reported with another supplement or medication
These studies reported worsening outcomes, reduced absorption, or other cautions with combined use. They do not predict an individual's outcome.
CilostazolCoadministration of Ginkgo biloba with cilostazol significantly potentiated the prolongation of bleeding time compared to individual doses.